Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $275
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $200 to $275.
June 24, 2024 | 6:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer maintains a Buy rating on Alnylam Pharmaceuticals and raises the price target from $200 to $275.
The raised price target from $200 to $275 by a reputable analyst suggests strong confidence in Alnylam Pharmaceuticals' future performance, likely leading to positive investor sentiment and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100